TD Cowen lifts target for UCB stock to EUR 340.00

Published on 10/26/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 4.27 billion in the June 30, 2026 period. UCB stock costs EUR 269.55 on October 26, 2026, down 1.16 percent versus the Xetra close.

Target and market position

TD Cowen maintained a Buy rating and lifted its UCB target from EUR 305.00 to EUR 340.00 on October 23, 2026.
UCB revenue reached EUR 4.27 billion for the period ended June 30, 2026, up 22.35 percent from EUR 3.49 billion.
UCB stock costs EUR 269.55 at Lang & Schwarz on October 26, 2026 at 4:35 p.m. CEST, down 1.16 percent versus the October 23, 2026 Xetra close.
The 52-week range is EUR 197.45 to EUR 289.50, leaving the stock 6.89 percent below its high.

UCB, BE0003739530, Illustration mit AI erstellt.

TD Cowen raised its target for UCB S.A. from EUR 305.00 to EUR 340.00 on October 23, 2026, while maintaining a Buy rating, according to Markets Insider. The target is 26.13 percent above the EUR 269.55 price. UCB stock was trading at EUR 269.55 at Lang & Schwarz on October 26, 2026 at 4:35 p.m. CEST, down 1.16 percent versus the Xetra close of October 23, 2026 at EUR 272.70.

Revenue growth remains visible

UCB reported revenue of EUR 4.27 billion for the period ended June 30, 2026, compared with EUR 3.49 billion in the comparable prior-year period. That represents growth of 22.35 percent. The figures and period were reported by Markets Insider.

UCB's investor materials identify BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak sales guidance above EUR 7.00 billion. The company also reported first-half sales of EUR 954.00 million for CIMZIA and EUR 239.00 million for FINTEPLA, according to UCB.

What does EUR 340.00 imply?

The TD Cowen target stands 26.13 percent above the Lang & Schwarz price, using the same euro denomination. The comparison matters because the stock is still 6.89 percent below its 52-week high of EUR 289.50 and 36.52 percent above its 52-week low of EUR 197.45.

Valuation and trading frame

UCB had a market capitalization of EUR 51.2 billion and a price-to-earnings ratio of 23.32 as of October 26, 2026. The Euronext Brussels quote was EUR 268.70 at 5:25 p.m. CEST, with volume of 143,524 shares. UCB is listed in Brussels and operates in biotechnology and biopharmaceutical research, with a portfolio centered on neurological and immunological diseases.

Analyst target sets the benchmark

TD Cowen's EUR 340.00 target is the clearest dated valuation marker in the latest coverage. Its EUR 35.00 increase from the previous target contrasts with the stock's 1.16 percent decline against the October 23, 2026 Xetra close, leaving the market price below both the new target and the 52-week high.

Stock position after the update

The stock remains within its documented yearly range, while the revenue comparison supplies a concrete operating measure alongside the analyst view. UCB's current valuation reflects a company with EUR 4.27 billion in revenue for the period ended June 30, 2026 and a sizeable commercial contribution from BIMZELX.

UCB stock was trading at EUR 269.55 at Lang & Schwarz on October 26, 2026 at 4:35 p.m. CEST, down 1.16 percent versus the Xetra close of October 23, 2026 at EUR 272.70. The further course of trading is shown by the continuously updated real-time quote of UCB stock.